208 related articles for article (PubMed ID: 17911019)
1. Novel scaffold for cathepsin K inhibitors.
Teno N; Miyake T; Ehara T; Irie O; Sakaki J; Ohmori O; Gunji H; Matsuura N; Masuya K; Hitomi Y; Nonomura K; Horiuchi M; Gohda K; Iwasaki A; Umemura I; Tada S; Kometani M; Iwasaki G; Cowan-Jacob SW; Missbach M; Lattmann R; Betschart C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6096-100. PubMed ID: 17911019
[TBL] [Abstract][Full Text] [Related]
2. Effect of cathepsin K inhibitors on bone resorption.
Teno N; Masuya K; Ehara T; Kosaka T; Miyake T; Irie O; Hitomi Y; Matsuura N; Umemura I; Iwasaki G; Fukaya H; Toriyama K; Uchiyama N; Nonomura K; Sugiyama I; Kometani M
J Med Chem; 2008 Sep; 51(17):5459-62. PubMed ID: 18707091
[TBL] [Abstract][Full Text] [Related]
3. 4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors.
Irie O; Yokokawa F; Ehara T; Iwasaki A; Iwaki Y; Hitomi Y; Konishi K; Kishida M; Toyao A; Masuya K; Gunji H; Sakaki J; Iwasaki G; Hirao H; Kanazawa T; Tanabe K; Kosaka T; Hart TW; Hallett A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4642-6. PubMed ID: 18662880
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
5. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
[TBL] [Abstract][Full Text] [Related]
7. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
8. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
[TBL] [Abstract][Full Text] [Related]
11. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
[TBL] [Abstract][Full Text] [Related]
13. Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.
Tavares FX; Deaton DN; Miller LR; Wright LL
J Med Chem; 2004 Oct; 47(21):5057-68. PubMed ID: 15456249
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.
Teno N; Gohda K; Wanaka K; Tsuda Y; Sueda T; Yamashita Y; Otsubo T
Bioorg Med Chem; 2014 Apr; 22(7):2339-52. PubMed ID: 24613052
[TBL] [Abstract][Full Text] [Related]
15. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
[TBL] [Abstract][Full Text] [Related]
16. 4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.
Shinozuka T; Shimada K; Matsui S; Yamane T; Ama M; Fukuda T; Taki M; Naito S
Bioorg Med Chem Lett; 2006 Mar; 16(6):1502-5. PubMed ID: 16380250
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
18. Novel and potent cyclic cyanamide-based cathepsin K inhibitors.
Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Shewchuk LM; Tavares FX; Willard DH; Wright LL
Bioorg Med Chem Lett; 2005 Apr; 15(7):1815-9. PubMed ID: 15780613
[TBL] [Abstract][Full Text] [Related]
19. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
[TBL] [Abstract][Full Text] [Related]
20. Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold.
Teno N; Masuya K
Curr Top Med Chem; 2010; 10(7):752-66. PubMed ID: 20337583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
